rhMG53 decreases membrane damage <i>in vitro</i>. by Brian J. Paleo (8694246)

Nrf2 activation decreases PMN ROS production in response to zymosan. by Doumet Georges Helou (7255823)

This is the raw data of IHC-2 、qPCR、Masson and HE in Rat、qPCR in human peritoneal solution and qPCR in Met-5A cell. by Yangyang Yin (14323701)

Subjects:

Demographics and baseline characteristics of the safety population. by Rahsan Erdem (11726357)

Subjects:

iOWH032 inhibits cholera toxin-induced secretion in a mouse closed-loop model. by Rahsan Erdem (11726357)

Subjects:

Grading of stool consistency and diarrhea severity. by Rahsan Erdem (11726357)

Subjects:

Secondary efficacy endpoints for the modified intent-to-treat population. by Rahsan Erdem (11726357)

Subjects:

Study drug–related treatment-emergent adverse events by system organ class and preferred term in the safety population. by Rahsan Erdem (11726357)

Subjects:

Source data for Fig 1. by Rahsan Erdem (11726357)

Subjects:

Diarrheal stool output rate overall and by blood type status in the modified intent-to-treat population. by Rahsan Erdem (11726357)

Subjects:

Source data for S1 and S2 Figs. by Rahsan Erdem (11726357)

Subjects:

Source data for Fig 2. by Rahsan Erdem (11726357)

Subjects:

Consolidated Standards for Reporting of Trials flow diagram. by Rahsan Erdem (11726357)

Subjects:

iOWH032 inhibits cholera toxin-induced fecal output in a cecectomized rat model. by Rahsan Erdem (11726357)

Subjects:

Source data for Fig 3. by Rahsan Erdem (11726357)

Subjects:

Scatterplot of iOWH032 plasma concentrations versus diarrheal stool output rate. by Rahsan Erdem (11726357)

Subjects:

Reverse cumulative distribution plot for diarrheal stool output rate overall in the modified intent-to-treat population. by Rahsan Erdem (11726357)

Subjects:

Diarrheal disease severity by treatment group for the modified intent-to-treat population. by Rahsan Erdem (11726357)

Subjects:

Overview of study procedures. by Matthew G. Vinson (22593374)

“…VIDEO and CONTROL were associated with a similar rise in intent to decrease OTC NSAID use (1.92 (SD: 4.41) vs. 1.36 (SD: 3.46), p = 0.150) and a similar decrease in NSAIDs exposure (−32.8% in VIDEO and −36.5% in CONTROL, p = 0.520) 4 weeks post-intervention. …”

Immunohistochemical analysis of p-Akt expression in various experimental groups showing negative expression in control group, marked increased expression along the extended fibrous... by Rehab F. Abdel-Rahman (11886404)